{"DataElement":{"publicId":"11232962","version":"1","preferredName":"Common Terminology Criteria for Adverse Events Ocular Occurrence Type","preferredDefinition":"A description of the ocular common terminology criteria adverse event occurrence.","longName":"CTCAE_OCULR_TYP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"11231450","version":"1","preferredName":"Common Terminology Criteria for Adverse Events Ocular Occurrence","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.:Of or relating to the eye._An instance of something happening, such as an event or incident.","longName":"2480706v1.00:11231449v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11231449","version":"1","preferredName":"Ocular Occurrence","preferredDefinition":"Of or relating to the eye._An instance of something happening, such as an event or incident.","longName":"C87163:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocular","conceptCode":"C87163","definition":"Of or relating to the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8901912-A738-3FEC-E053-731AD00AD45B","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8901912-A739-3FEC-E053-731AD00AD45B","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-28","changeDescription":null,"administrativeNotes":"2022.9.13 Created for ticket request CADSR0001486. ak 2022.9.28 Released per closed ticket. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11232890","version":"1","preferredName":"Ocular Common Terminology Criteria for Adverse Events Type","preferredDefinition":"Of or relating to the eye._A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event._Something distinguishable as an identifiable class based on common qualities.","longName":"OCULR_CTCAE_TYP","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Corneal edema","valueDescription":null,"ValueMeaning":{"publicId":"4394834","version":"1","preferredName":"Corneal Edema","longName":"4394834","preferredDefinition":"Hazy, swollen cornea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corneal Edema","conceptCode":"C50508","definition":"Hazy, swollen cornea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB5698F-C5D8-FBDD-E040-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF43-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Hyphema","valueDescription":null,"ValueMeaning":{"publicId":"4394863","version":"1","preferredName":"Hyphema","longName":"4394863","preferredDefinition":"Hemorrhage within the anterior chamber of the eye; bloodshot.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyphema","conceptCode":"C50592","definition":"Hemorrhage within the anterior chamber of the eye; bloodshot.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB5698F-C88C-FBDD-E040-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF44-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Intraocular pressure","valueDescription":null,"ValueMeaning":{"publicId":"6677766","version":"1","preferredName":"Intraocular Pressure","longName":"6677766","preferredDefinition":"The fluid pressure within the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraocular Pressure","conceptCode":"C87143","definition":"The fluid pressure within the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8489015F-D411-5A58-E053-F662850A539F","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF45-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Anterior uveitis","valueDescription":null,"ValueMeaning":{"publicId":"11232891","version":"1","preferredName":"Anterior Uveitis","longName":"11232891v1.00","preferredDefinition":"Inflammation of the iris and anterior chamber of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anterior Uveitis","conceptCode":"C35109","definition":"Inflammation of the iris and anterior chamber of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890BC7E-CF3F-5A80-E053-731AD00A725F","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF46-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Posterior uveitis","valueDescription":null,"ValueMeaning":{"publicId":"11232893","version":"1","preferredName":"Posterior Uveitis","longName":"11232893v1.00","preferredDefinition":"An inflammatory process that affects the choroid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posterior Uveitis","conceptCode":"C35111","definition":"An inflammatory process that affects the choroid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890BC7E-CF41-5A80-E053-731AD00A725F","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF47-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Panuveitis","valueDescription":null,"ValueMeaning":{"publicId":"3211338","version":"1","preferredName":"Panuveitis","longName":"3211338","preferredDefinition":"A disorder characterized by inflammation of the entire uvea which includes the iris, ciliary body, and choroid. Causes include systemic infections, sarcoidosis, and cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panuveitis","conceptCode":"C84989","definition":"A disorder characterized by inflammation of the entire uvea which includes the iris, ciliary body, and choroid. Causes include systemic infections, sarcoidosis, and cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EFEB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF48-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Lens opacity","valueDescription":null,"ValueMeaning":{"publicId":"11232894","version":"1","preferredName":"Lens Opacity","longName":"11232894v1.00","preferredDefinition":"A biconvex transparent structure of the eye through which light is focused on the retina. The lens sits behind the iris and is supported by the zonule, which connects it to the ciliary body. The lens is an avascular structure._The quality of being opaque to a degree; the degree to which something reduces the passage of light.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lens","conceptCode":"C12743","definition":"A biconvex transparent structure of the eye through which light is focused on the retina. The lens sits behind the iris and is supported by the zonule, which connects it to the ciliary body. The lens is an avascular structure.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Opacity","conceptCode":"C71596","definition":"The quality of being opaque to a degree; the degree to which something reduces the passage of light.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890BC7E-CF42-5A80-E053-731AD00A725F","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF49-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Vitreous hemorrhage","valueDescription":null,"ValueMeaning":{"publicId":"2943859","version":"1","preferredName":"Vitreous Hemorrhage","longName":"2943859","preferredDefinition":"Blood extravasation in the vitreous humor. Causes include neovascularization, retinal tear, retinal detachment, and rupture of a blood vessel aneurysm in the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitreous Hemorrhage","conceptCode":"C50469","definition":"Blood extravasation in the vitreous humor. Causes include neovascularization, retinal tear, retinal detachment, and rupture of a blood vessel aneurysm in the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7429EDA1-5726-380A-E040-BB89AD432D62","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF4A-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Retinal detachment","valueDescription":null,"ValueMeaning":{"publicId":"2944682","version":"1","preferredName":"Retinal Detachment","longName":"2944682","preferredDefinition":"An eye emergency condition which may lead to blindness if left untreated. It is characterized by the separation of the inner retina layers from the underlying pigment epithelium. Causes include trauma, advanced diabetes mellitus, high myopia, and choroid tumors. Symptoms include sudden appearance of floaters, sudden light flushes, and blurred vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinal Detachment","conceptCode":"C26874","definition":"An eye emergency condition which may lead to blindness if left untreated. It is characterized by the separation of the inner retina layers from the underlying pigment epithelium. Causes include trauma, advanced diabetes mellitus, high myopia, and choroid tumors. Symptoms include sudden appearance of floaters, sudden light flushes, and blurred vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74419E3D-8A03-7FAC-E040-BB89AD434C1B","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-23","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF4B-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Intermediate uveitis","valueDescription":null,"ValueMeaning":{"publicId":"11232892","version":"1","preferredName":"Intermediate Uveitis","longName":"11232892v1.00","preferredDefinition":"Inflammation of the pars plana.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intermediate Uveitis","conceptCode":"C35110","definition":"Inflammation of the pars plana.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890BC7E-CF40-5A80-E053-731AD00A725F","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890BC7E-CF4C-5A80-E053-731AD00A725F","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Conjunctiva response","valueDescription":null,"ValueMeaning":{"publicId":"11232895","version":"1","preferredName":"Conjunctiva Response","longName":"11232895v1.00","preferredDefinition":"A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball)._Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conjunctiva","conceptCode":"C12341","definition":"A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E692-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E69A-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Retinal toxicity","valueDescription":null,"ValueMeaning":{"publicId":"11232896","version":"1","preferredName":"Retinal Toxicity","longName":"11232896v1.00","preferredDefinition":"Of, relating to, or involving the retina._The finding of bodily harm due to the poisonous effects of something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinal","conceptCode":"C87176","definition":"Of, relating to, or involving the retina.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E693-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E69B-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Retinal inflammation","valueDescription":null,"ValueMeaning":{"publicId":"11232897","version":"1","preferredName":"Retinal Inflammation","longName":"11232897v1.00","preferredDefinition":"Of, relating to, or involving the retina._A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinal","conceptCode":"C87176","definition":"Of, relating to, or involving the retina.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Inflammation","conceptCode":"C3137","definition":"A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E694-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E69C-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Pupillary synechia","valueDescription":null,"ValueMeaning":{"publicId":"11232899","version":"1","preferredName":"Pupillary synechia","longName":"11232899v1.00","preferredDefinition":"Pupillary synechia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E696-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E69D-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Iris atrophy","valueDescription":null,"ValueMeaning":{"publicId":"11232900","version":"1","preferredName":"Iris Atrophy","longName":"11232900v1.00","preferredDefinition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber._Any weakening or degeneration, especially through lack of use.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iris","conceptCode":"C12737","definition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Atrophy","conceptCode":"C79748","definition":"Any weakening or degeneration, especially through lack of use.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E697-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E69E-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Endophthalmitis","valueDescription":null,"ValueMeaning":{"publicId":"2944490","version":"1","preferredName":"Endophthalmitis","longName":"2944490","preferredDefinition":"An infectious process affecting the internal structures of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endophthalmitis","conceptCode":"C34586","definition":"An infectious process affecting the internal structures of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74391E34-A8F3-C759-E040-BB89AD4304D8","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E69F-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Scleral necrosis","valueDescription":null,"ValueMeaning":{"publicId":"11232901","version":"1","preferredName":"Sclera Disorder Necrotic Process","longName":"11232901v1.00","preferredDefinition":"A disorder affecting the sclera. Examples include inflammatory processes (e.g., scleritis and episcleritis), and degenerative processes. Primary tumors of the sclera are extremely rare._A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sclera Disorder","conceptCode":"C79717","definition":"A disorder affecting the sclera. Examples include inflammatory processes (e.g., scleritis and episcleritis), and degenerative processes. Primary tumors of the sclera are extremely rare.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Necrotic Process","conceptCode":"C16897","definition":"A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E698-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E6A0-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Choroidal atrophy","valueDescription":null,"ValueMeaning":{"publicId":"3210960","version":"1","preferredName":"Choroideremia","longName":"3210960","preferredDefinition":"A rare, X-linked inherited disorder characterized by choroid atrophy and retinal degeneration. It leads to progressive loss of vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroideremia","conceptCode":"C34469","definition":"A rare, X-linked inherited disorder characterized by choroid atrophy and retinal degeneration. It leads to progressive loss of vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BA3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E6A1-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Retinal vascular occlusion","valueDescription":null,"ValueMeaning":{"publicId":"11232902","version":"1","preferredName":"Retinal Vascular Occlusion","longName":"11232902v1.00","preferredDefinition":"An occlusion of the retinal vasculature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinal Vascular Occlusion","conceptCode":"C34980","definition":"An occlusion of the retinal vasculature.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E699-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E6A2-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Optic nerve toxicity","valueDescription":null,"ValueMeaning":{"publicId":"11232898","version":"1","preferredName":"Optic Nerve Toxicity","longName":"11232898v1.00","preferredDefinition":"The second cranial nerve._The finding of bodily harm due to the poisonous effects of something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Optic Nerve","conceptCode":"C12761","definition":"The second cranial nerve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890CCF1-E695-5C1C-E053-731AD00A2BC6","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E890CCF1-E6A3-5C1C-E053-731AD00A2BC6","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008573","version":"1","preferredName":"Adverse Event Results","preferredDefinition":"the outcome or resolution of the patient's adverse events.","longName":"AE_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB869948-5E78-2537-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"11232889","version":"1","preferredName":"Ocular Common Terminology Criteria for Adverse Events Type","preferredDefinition":"Of or relating to the eye._A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event._Something distinguishable as an identifiable class based on common qualities.","longName":"11232889v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocular","conceptCode":"C87163","definition":"Of or relating to the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890A3D7-396A-581B-E053-731AD00AC132","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E890A3D7-396B-581B-E053-731AD00AC132","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-28","changeDescription":null,"administrativeNotes":"2022.9.13 Created for ticket request CADSR0001486. ak 2022.9.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the ocular common terminology criteria adverse event that occurred.","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Ocular toxicity adverse event term:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8912CEC-8C54-6737-E053-731AD00ADC65","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-28","changeDescription":null,"administrativeNotes":"2022.9.13 Created for ticket request CADSR0001486. ak 2022.9.28 Released per closed ticket. ak","unresolvedIssues":null,"deletedIndicator":"No"}}